Search clinical trials for: Lantus (glargine)

Total 1019 results

Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)

Type 2 Diabetes Mellitus

Korea, Republic of
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
São Paulo State University

Completed

The Prebiotic Effect of Daily Intake of Orange Juice Affects the Bioavailability of Flavanones?

Intestinal Diseases

Brazil
GlaxoSmithKline

Completed

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Russian Federation, United Kingdom, South Africa
Eli Lilly and Company

Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Self Titration With Apidra to Reach Target Study (START)

Diabetes Mellitus, Type 2

Canada
Sanofi

Terminated

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care (RELIANCE)

Diabetes Mellitus, Type 2

Australia
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Italy, Russian Federation, Slovakia, Spain, Ireland, Germany, Turkey, Bulgaria, Hong Kong, Romania, South Africa
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
University of Palermo

Completed

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Diabetes Mellitus

Italy
Emory University

Completed

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (SITA-CABGDM)

Hyperglycemia

United States
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Healthy Volunteers

Healthy | Diabetes

Germany
HaEmek Medical Center, Israel

Completed

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

Diabetes Mellitus Type 2
Eli Lilly and Company

Completed

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) (AWARD-7)

Type 2 Diabetes | Chronic Kidney Disease

Mexico, United States, Hungary, Ukraine, Brazil, Spain, Romania, South Africa, Poland
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study in Adults With Type 1 Diabetes (ELEMENT 1)

Diabetes Mellitus, Type 1

Japan, United States, Greece, Belgium, Poland, Germany, Hungary, Mexico, Romania
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Japan, Mexico, Russian Federation, Netherlands, Belgium, Italy, India, Romania
Eli Lilly and Company

Completed

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

Type 1 Diabetes | Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, France, United Kingdom, Russian Federation, Germany, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
LMC Diabetes & Endocrinology Ltd.
Sanofi

Completed

Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration (INNOVATE)

Type 2 Diabetes Mellitus

Canada
Eli Lilly and Company
Alkermes, Inc.

Completed

A Study for Patients With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan, Taiwan
Sanofi

Completed

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Ivano-Frankivsk National Medical University
Bionorica SE

Completed

Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute Tonsillitis

Acute Tonsillitis

Ukraine
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
Eli Lilly and Company

Completed

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Type 1 Diabetes

China
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, South Africa, Canada
Sanofi

Completed

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

Diabetes Mellitus, Type 2

Israel
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (LixiLan-G)

Type 2 Diabetes Mellitus

Estonia, Italy, Israel, United States, Canada, Germany, Romania, Slovakia, Spain
OAD Orthopaedics

Unknown

A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon

Achilles Tendinopathy

United States
Imperial College London

Completed

Human Urinary Biomarker for Orange Juice Consumption

Healthy

United Kingdom
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1

United States, Brazil
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Sweden, Norway, Germany, Australia
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Eli Lilly and Company

Completed

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Greece, India, Netherlands, Poland, Puerto Rico
University of Giessen
Sanofi

Completed

Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes (ClampHOE901)

Diabetes

Germany
Universidad de Granada

Recruiting

Validity of the Vyntus CPX Metabolic Cart for Assessing Postprandial Energy Expenditure and Respiratory Exchange Ratio

Metabolic Syndrome

Spain
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2

Turkey
Sanofi

Completed

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

France, Russian Federation, Croatia, Slovenia, Czech Republic, Romania
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden

3

Subscribe